APA (7th ed.) Citation

Xu, L., Chen, J., Liu, C., Song, X., Zhang, Y., Zhao, H., . . . Chen, M. (2024). Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma. BMC Medicine, 22(1), 1. https://doi.org/10.1186/s12916-024-03356-5

Chicago Style (17th ed.) Citation

Xu, Li, et al. "Efficacy and Safety of Tislelizumab Plus Lenvatinib as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma." BMC Medicine 22, no. 1 (2024): 1. https://doi.org/10.1186/s12916-024-03356-5.

MLA (9th ed.) Citation

Xu, Li, et al. "Efficacy and Safety of Tislelizumab Plus Lenvatinib as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma." BMC Medicine, vol. 22, no. 1, 2024, p. 1, https://doi.org/10.1186/s12916-024-03356-5.